MA54075A - Anticorps monoclonaux antirabiques et cocktail correspondant - Google Patents

Anticorps monoclonaux antirabiques et cocktail correspondant

Info

Publication number
MA54075A
MA54075A MA054075A MA54075A MA54075A MA 54075 A MA54075 A MA 54075A MA 054075 A MA054075 A MA 054075A MA 54075 A MA54075 A MA 54075A MA 54075 A MA54075 A MA 54075A
Authority
MA
Morocco
Prior art keywords
rabs
monoclonal antibodies
cocktail
corresponding cocktail
monoclonal
Prior art date
Application number
MA054075A
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Pankaj Kalita
Kevinkumar Kansagra
Sanjeev Kumar Mendiratta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA54075A publication Critical patent/MA54075A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054075A 2018-11-02 2019-10-24 Anticorps monoclonaux antirabiques et cocktail correspondant MA54075A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821041598 2018-11-02

Publications (1)

Publication Number Publication Date
MA54075A true MA54075A (fr) 2022-02-09

Family

ID=68655573

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054075A MA54075A (fr) 2018-11-02 2019-10-24 Anticorps monoclonaux antirabiques et cocktail correspondant

Country Status (9)

Country Link
EP (1) EP3873526B1 (fr)
CN (1) CN113226372A (fr)
BR (1) BR112021008240A2 (fr)
EC (1) ECSP21039816A (fr)
MA (1) MA54075A (fr)
MX (1) MX2021005029A (fr)
PE (1) PE20211056A1 (fr)
PH (1) PH12021550987A1 (fr)
WO (1) WO2020089742A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048130A2 (fr) * 2011-09-30 2013-04-04 (주)셀트리온 Molécule de liaison pour neutraliser un virus de la rage
LT3220947T (lt) * 2014-11-18 2020-12-28 Humabs Biomed S.A. Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
US10450367B2 (en) * 2015-08-13 2019-10-22 University Of Massachusetts Human antibodies against rabies and uses thereof

Also Published As

Publication number Publication date
MX2021005029A (es) 2021-07-15
PE20211056A1 (es) 2021-06-07
ECSP21039816A (es) 2021-09-30
EP3873526A1 (fr) 2021-09-08
CN113226372A (zh) 2021-08-06
WO2020089742A1 (fr) 2020-05-07
BR112021008240A2 (pt) 2021-10-26
PH12021550987A1 (en) 2021-11-08
EP3873526B1 (fr) 2024-09-04

Similar Documents

Publication Publication Date Title
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA52212A (fr) Anticorps multivalent
EP3473649A4 (fr) Anticorps monoclonal anti-cd47 et application correspondante
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3849598A4 (fr) Anticorps agonistes anti-trem-2
EP4261231A4 (fr) Anticorps bispécifique et application correspondante
IL283104A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
EP3589660A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3587453A4 (fr) Anticorps anti-pd-l1 et son application
EP4019550A4 (fr) Anticorps anti-pd-l1 à domaine unique
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3752536A4 (fr) Anticorps anti-her2
MA52152A (fr) Anticorps
EP3480216A4 (fr) Anticorps monoclonal anti-pcsk9
EP3831851A4 (fr) Anticorps anti-btla
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP3613770A4 (fr) Anticorps monoclonal à pd-l1
EP3733713A4 (fr) Anticorps bispécifique et ses applications
EP3746120A4 (fr) Anticorps anti-pd-1